Skip to main content

Medline Inc.

MDLN
Exchange
Nasdaq
Industry
Surgical & Medical Instruments & Apparatus
SEC CIK
0002046386

In the last 90 days, Medline Inc. insiders filed 0 open-market purchases and 2 sales; 414 institutions reported holding it in 13F filings for Q3 2026, worth $30.3B in total; 4 superinvestors hold it, including Lone Pine Capital and Maverick Capital.

Currency
USD
Source
SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
Updated
Nov 5, 2026, 12:25 AM ET

Revenue flow, FY2025

Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.

Income statement

Each column is one fiscal year, newest first.

Income statement of Medline Inc., annual
Line itemFY2025
Period endDec 31, 2025
Filing10-K
ReportedFeb 25, 2026
Revenue$28.4B
Cost of revenue$20.9B
Gross profit$7.52B
Operating expenses$5.31B
Research and development$80.0M
Selling, general and administrative$4.52B
Operating income$2.21B
Income tax$91.0M
Net income$1.16B
EPS, basic$-0.01
EPS, diluted$-0.01
Weighted shares, basic810.0M
Weighted shares, diluted810.0M
Margins and growth
Gross margin26.4%
Operating margin7.8%
Net margin4.1%

Balance sheet

Each column is one fiscal year, newest first.

Balance sheet of Medline Inc., annual
Line itemFY2025
Period endDec 31, 2025
Filing10-K
ReportedFeb 25, 2026
Cash and equivalents$1.94B
Accounts receivable$3.53B
Inventory$4.77B
Total current assets$10.7B
Property, plant and equipment$4.78B
Goodwill$8.08B
Intangible assets$13.9B
Total assets$38.5B
Accounts payable$961.0M
Short-term debt$1.00M
Total current liabilities$2.49B
Long-term debt$12.5B
Total liabilities$19.2B
Shareholders' equity$19.3B

Cash flow statement

Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.

Cash flow statement of Medline Inc., annual
Line itemFY2025
Period endDec 31, 2025
Filing10-K
ReportedFeb 25, 2026
Operating cash flow$1.74B
Capital expenditures$447.0M
Free cash flow$1.30B
Depreciation and amortization$1.01B
Stock-based compensation$76.0M
Share buybacks$33.0M
Investing cash flow-$474.0M
Financing cash flow$399.0M
Net change in cash$1.69B
Ratio
Stock-based compensation, % of revenue0.3%

Shares outstanding

Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.

Shares outstanding for Medline Inc. by cover date
Cover dateShares outstandingChange in a yearFiling
Nov 2, 20261.32B–SEC

Notes and known gaps

How these numbers are put together, and what they can't tell you.

  • Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
  • Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.

Known gaps

  • Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
  • EPS and share counts are as reported at the time, not adjusted for later stock splits.
  • For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
  • For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
  • Companies with several share classes, such as Berkshire Hathaway, may have no EPS. Their cover share count adds up the classes but only for the last few filings, so there can be a gap before them.
  • Depreciation and amortization is missing for some companies that report it under their own XBRL tags.